SCHEMBL667359

SCHEMBL667359

CC(=O)NCCc1cc[c]cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.65
F13A1 P00488 1/20 0.65
SMN1; SMN2 Q16637 2/20 0.59
ALDH1A1 P00352 3/20 0.54
HPGD P15428 2/20 0.54
LMNA P02545 1/20 0.54
MAPT P10636 1/20 0.54
PTGS1 P23219 1/20 0.54
BLM P54132 1/20 0.54
HIF1A Q16665 1/20 0.54
HSD17B10 Q99714 1/20 0.54
ACACB O00763 4/20 0.49
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC11 Q96DB2 1/20 0.44
HDAC8 Q9BY41 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10592850 0.86 KDM4E (0.84) KDM4EF13A1SMN1; SMN2ALDH1A1HPGD
SCHEMBL1979285 0.84 KDM4E (0.46) KDM4EF13A1SMN1; SMN2ALDH1A1HPGD
SCHEMBL9799589 0.81 GLA (0.50) KDM4EF13A1SMN1; SMN2ALDH1A1HDAC3
SCHEMBL5186025 0.80 KMT2A (0.57) KDM4EF13A1LMNA
SCHEMBL754248 0.80 KMT2A (0.58) KDM4ESMN1; SMN2ALDH1A1MAPTHDAC3
SCHEMBL7858 0.80 KDM4E (0.69) KDM4EF13A1SMN1; SMN2ALDH1A1HPGD
SCHEMBL1561302 0.79 KDM4E (0.53) KDM4EF13A1SMN1; SMN2ALDH1A1HPGD
SCHEMBL734658 0.78 KDM4E (1.00) KDM4EF13A1SMN1; SMN2ALDH1A1HPGD
SCHEMBL661278 0.78 KDM4E (0.72) KDM4EF13A1SMN1; SMN2ALDH1A1HPGD
SCHEMBL6845396 0.78 KDM4E (0.72) KDM4EF13A1SMN1; SMN2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1131290-B1 PIPERIDINE CCR-3 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2008-02-20 EP claimed
EP-0903349-B1 CCR-3 receptor antagonists HOFFMANN LA ROCHE (CH) 2006-01-04 EP claimed
US-20040266782-A1 Cyclic amine derivatives-CCR-3 receptor antagonists GONG LEYI (US) 2004-12-30 US claimed
EP-1131291-B1 4-AROYL-PIPERIDIN-CCR-3 RECEPTOR ANTAGONISTS III HOFFMANN LA ROCHE (CH) 2004-10-20 EP claimed
US-20030153577-A1 Cyclic amine derivatives-CCR-3 receptor antagonists ROCHE BIOSCIENCE 2003-08-14 US claimed
CN-1107061-C Cyclic amine derivatives-CCR-3 receptor antagonists HOFFMANN LA ROCHE (CH) 2003-04-30 CN claimed
US-6342509-B1 ANTIASTHMATICS, ANTIHISTAMINES OR BRONCHODIALATORS SYNTEX (U.S.A.) LLC 2002-01-29 US claimed
US-6339087-B1 FOR THERAPY OF INFLAMMATORY OR ALLERGIC DISEASES ARE SELECTED FROM ASTHMA, ALLERGIC RHINITIS, HYPERSENSITIVITY LUNG DISEASES, HYPERSENSITIVITY PNEUMONITIS, EOSINOPHILIC PNEUMONIAS, INFLAMMATORY BOWEL DISEASES, PSORIASIS, DERMATITIS SYNTEX (U.S.A.) LLC 2002-01-15 US claimed
US-6323223-B1 CCR-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, METHODS FOR THEIR USE AND METHODS FOR PREPARING THESE COMPOUNDS. SYNTEX (U.S.A.) LLC 2001-11-27 US claimed
EP-1131291-A1 4-AROYL-PIPERIDIN-CCR-3 RECEPTOR ANTAGONISTS III F. HOFFMANN-LA ROCHE AG (CH) 2001-09-12 EP claimed
EP-1131290-A1 PIPERIDINE CCR-3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2001-09-12 EP claimed
US-6140344-A FOR TREATING PATHOLOGICAL CONDITIONS SUCH AS ASTHMA, RHINITIS, ECZEMA AND PARASITIC INFECTIONS FEATURING TISSUE EOSINOPHILIA SYNTEX (U.S.A.) INC. (US) 2000-10-31 US claimed
WO-2000031033-A1 PIPERIDINE CCR-3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2000-06-02 WO claimed
WO-2000029377-A1 4-AROYL-PIPERIDIN-CCR-3 RECEPTOR ANTAGONISTS III F. HOFFMANN-LA ROCHE AG (CH) 2000-05-25 WO claimed
EP-0903349-A2 CCR-3 receptor antagonists F. HOFFMANN-LA ROCHE AG (CH) 1999-03-24 EP claimed
CN-1211572-A Cyclic amine derivatives-CCR-3 receptor antagonists HOFFMANN LA ROCHE (CH) 1999-03-24 CN claimed
EP-0193227-B1 PROCESS FOR THE PREPARATION OF ARYLGLYCIDYL ETHERS AND 3-SUBSTITUTED 1-ALKYLAMINO-2-PROPANOLS GIST-BROCADES N.V. (NL) 1990-04-11 EP claimed
EP-0193227-A1 Process for the preparation of arylglycidyl ethers and 3-substituted 1-alkylamino-2-propanols GIST-BROCADES N.V. (NL) 1986-09-03 EP claimed
US-4363808-A N-(3-Phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines BERLEX LABORATORIES, INC. (US) 1982-12-14 US claimed
EP-0034116-A2 N-(3-phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines BERLEX LABORATORIES, INC. (US) 1981-08-19 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266782-A1 Cyclic amine derivatives-CCR-3 receptor antagonists CCR3, CCR1, CCRL2 KDM4E 3302/4885F13A1 1479/4885SMN1; SMN2 3154/4885
US-20030153577-A1 Cyclic amine derivatives-CCR-3 receptor antagonists CCR3, CCR1, CCRL2 KDM4E 3302/4885F13A1 1479/4885SMN1; SMN2 3154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.